NEW YORK, NY / ACCESSWIRE / April 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
BELLUS Health Inc. (NASDAQ:BLU)
CONTACT JAKUBOWITZ ABOUT BLU:
https://claimyourloss.com/securities/bellus-health-inc-loss-submission-form/?id=14632&from=1
Class Period : September 5, 2019 - July 5, 2020
Lead Plaintiff Deadline : May 17, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: while BLU-5937’s “high selectivity” contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company’s Phase 2 trial.
Ehang Holdings Limited (NASDAQ:EH)
CONTACT JAKUBOWITZ ABOUT EH:
https://claimyourloss.com/securities/ehang-holdings-limited-loss-submission-form/?id=14632&from=1
Class Period : December 12, 2019 - February 16, 2021
Lead Plaintiff Deadline : April 19, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s purported regulatory approvals in Europe and North American for its EH216 were for use as a drone, and not for carrying passengers; (ii) its relationship with its purported primary customer is a sham; (iii) EHang has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; (iv) the Company’s manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
CytoDyn Inc. (OTCMKT:CYDY)
CONTACT JAKUBOWITZ ABOUT CYDY:
https://claimyourloss.com/securities/cytodyn-inc-loss-submission-form/?id=14632&from=1
Class Period : March 27, 2020 - March 9, 2021
Lead Plaintiff Deadline : May 17, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: CytoDyn securities were actively traded over the counter (OTC) in the United States. While the exact number of Class members is unknown to Plaintiff at this time and can be ascertained only through appropriate discovery, Plaintiff believes that there are hundreds or thousands of members in the proposed Class. Record owners and other members of the Class may be identified from records maintained by CytoDyn or its transfer agent and/or OTC Markets and may be notified of the pendency of this action by mail, using the form of notice similar to that customarily used in securities class actions.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law